Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
About this trial
This is an interventional treatment trial for Childhood Malignant Fibrous Histiocytoma of Bone focused on measuring metastatic osteosarcoma, recurrent childhood rhabdomyosarcoma, recurrent osteosarcoma, embryonal childhood rhabdomyosarcoma, alveolar childhood rhabdomyosarcoma, pleomorphic childhood rhabdomyosarcoma, metastatic childhood soft tissue sarcoma, recurrent childhood soft tissue sarcoma, childhood fibrosarcoma, childhood synovial sarcoma, childhood liposarcoma, childhood alveolar soft-part sarcoma, childhood neurofibrosarcoma, childhood angiosarcoma, childhood malignant fibrous histiocytoma of bone, previously treated childhood rhabdomyosarcoma, metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor, fibrosarcomatous osteosarcoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic or unresectable locally advanced (stage IV or recurrent) soft tissue or bone sarcoma Eligible subtypes: Ewing's family (e.g., primitive neuroectodermal tumor) Osteosarcoma Synovial sarcoma Rhabdomyosarcoma (e.g., alveolar, embryonal, or pleomorphic) Liposarcoma (all variants) Malignant fibrous histiocytoma Peripheral nerve sheath (e.g., malignant peripheral nerve sheath tumor, neurofibrosarcoma, or schwannoma) Fibrosarcoma Angiosarcoma (all variants) Failed standard therapy with no available salvage regimens Unidimensionally measurable target lesions by x-ray, CT scan, MRI, PET, or physical examination Must be outside prior irradiation fields or have documented disease progression at least 6 weeks after completion of prior radiotherapy PATIENT CHARACTERISTICS: Age: 10 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 3 times upper limit of normal (ULN) ALT and AST less than 2.5 times ULN Renal: Creatinine less than 1.5 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception during and for at least 1 week after study participation for female patients and for at least 3 months after study participation for male patients PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: No hormonal birth control Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy and recovered Surgery: Not specified Other: At least 28 days since any prior systemic therapy
Sites / Locations
- Jonsson Comprehensive Cancer Center, UCLA
- Washington Hospital Center
- Lutheran General Cancer Care Center
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
- University of Michigan Comprehensive Cancer Center
- Mayo Clinic Cancer Center
- Memorial Sloan-Kettering Cancer Center
- Herbert Irving Comprehensive Cancer Center at Columbia University
- University of Texas - MD Anderson Cancer Center